Drug intelligence / Profile preview

Greer lab allergen extract diluent

Development stage: Unknown
Lead developer: Greer Laboratories
Modality: Small Molecules
Administration: Inhalation

Overview

Greer lab allergen extract diluent is a specialized solution used as a vehicle for allergen extracts in clinical research and diagnostic testing. In the Phase 1 study 'Genetics of Environmental Asthma' led by John Sundy, this diluent was administered via nebulized inhalation to subjects with atopic asthma and healthy controls to serve as a baseline control for gene expression analysis. The formulation consists of 0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin, and 0.4% phenol, designed to maintain the stability of allergens like house dust mite while being suitable for inhalation.

Other names: diluentGreer lab allergen extract diluentallergen extract diluent

Beyond the preview

Go deeper on Greer lab allergen extract diluent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Greer lab allergen extract diluent.

Explore the full profile